Pfizer Ventures invests in areas of current or future strategic interest to Pfizer with the goal of remaining at the forefront of life science advances. They identify and invest in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’s pipeline and shape the future of our industry.
They investments are focused on potentially transformative therapeutics, with an emphasis in our core therapeutic areas: Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease, and Vaccines. They also consider platform technologies, diagnostics, drug delivery, pharmaceutical services, and other technologies that have the potential to transform drug discovery and development.
With a $600M capital commitment for investment, Pfizer Ventures backs private companies at all stages of development. They have a strong focus on early-stage opportunities. But other investments, including start-ups and spinouts, are also considered in scope. While primarily U.S. focused, international investments may represent up to 20 percent of the portfolio. They can lead or join a syndicate of investors and will seek board representation commensurate with our investment.
https://www.pfizer.com/about/partners/submit-your-opportunities
